Mesoblast (ASX:MSB) Accounts Payable & Accrued Expense : A$18.73 Mil (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast Accounts Payable & Accrued Expense?

Mesoblast's quarterly accounts payable & accrued expense declined from Jun. 2024 (A$10.65 Mil) to Sep. 2024 (A$0.00 Mil) but then increased from Sep. 2024 (A$0.00 Mil) to Dec. 2024 (A$18.73 Mil).

Mesoblast's annual accounts payable & accrued expense declined from Jun. 2022 (A$32.84 Mil) to Jun. 2023 (A$30.02 Mil) and declined from Jun. 2023 (A$30.02 Mil) to Jun. 2024 (A$10.65 Mil).

Mesoblast Accounts Payable & Accrued Expense Historical Data

The historical data trend for Mesoblast's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Accounts Payable & Accrued Expense Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

36.18

25.63

32.84

30.02

10.65

Mesoblast Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															-	10.65	-	18.73	-

Mesoblast Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany LWB1:Germany LWB:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.